IFF

International Flavors & Fragrances

$79.62

+1.28%
Nov 20, 2026
Bobby Quantitative Model
International Flavors & Fragrances is the world's largest specialty ingredients producer, selling proprietary flavor, fragrance, health and bioscience, and food ingredient formulations to customers across food and beverage, household goods, personal care, and pharmaceutical end markets. Its competitive identity rests on a moat built from proprietary formulation IP, deep co-development relationships with global consumer brands, and a portfolio that spans Taste (~25% of profits), Scent (~25%), and Health & Biosciences (~30%, a global leader in probiotics and enzymes), making it a toll-taker on consumer staples demand rather than a commodity chemical cyclical. The current investor narrative is a self-help and portfolio-simplification story: management is divesting the lower-margin Food Ingredients business in a deal expected to close in 2027, leaving a higher-growth, higher-margin core, while the market debates whether cost discipline and debt paydown can translate into durable earnings recovery after a multi-year stretch of goodwill impairments and restructuring charges. Recent attention has centered on the Q3 2026 print, which showed a sharp revenue decline alongside a swing to a net loss, and on whether the announced divestiture proceeds and buyback activity can re-rate a stock that has nonetheless outperformed the S&P 500 over the past year.

People also watch

Ecolab

Ecolab

ECL

Analysis
Sherwin-Williams

Sherwin-Williams

SHW

Analysis
Air Products & Chemicals

Air Products & Chemicals

APD

Analysis
PPG Industries

PPG Industries

PPG

Analysis
LyondellBasell

LyondellBasell

LYB

Analysis

BobbyInvestment Opinion: Should I buy IFF Today?

Rating: Hold with a constructive bias — the risk/reward is skewed favorably (roughly 21% upside to the $98.24 average target versus only about 6.4% downside to the $76 low target), but the P&L does not yet validate the thesis. The core reasoning is that IFF is a self-help and portfolio-simplification story whose value depends on the Food Ingredients divestiture closing in 2027 and on cost discipline converting a 42.48% gross margin into something closer to a double-digit operating margin than the current 7.73%. The 14-Buy/5-Hold/1-Sell consensus with a 1.9 recommendation mean confirms the sell-side is already positioned for that outcome, which limits how much incremental re-rating a Hold-rated investor can capture before the catalyst actually lands.

Supporting evidence is mixed but leans toward the bull side on valuation and toward the bear side on momentum. On the positive side: gross margin expanded to 42.48% in Q3 2026 from 36.49% a year earlier; price-to-book of 1.22x sits near the bottom of its multi-year 1.02x–1.82x band; price-to-sales of 1.58x is modest in absolute terms for a 42%-gross-margin franchise; and the $98.24 average target implies roughly 21% upside from $81.16. On the negative side: revenue fell 27.91% year over year to $1.942 billion, Q3 swung to a $55 million net loss (EPS -$0.22), trailing EPS is -$0.02 making the trailing PE of -46.16x meaningless, and the 20.99x forward PE rests entirely on consensus EPS of $4.864 that has not yet materialized. Free cash flow of $499 million TTM is only a ~2.9% yield on the $17.25 billion market cap, and Q3 FCF was actually -$7 million while $513 million of buybacks were executed — a capital-return program dependent on divestiture proceeds rather than organic cash generation.

The three biggest risks that could invalidate the thesis are: (1) the Food Ingredients divestiture slipping past 2027 or pricing below expectations, which would remove both the debt-paydown funding and the re-rating catalyst; (2) Q4 results confirming rather than arresting the revenue erosion, which would push analysts toward the $76 low target and likely compress the 20.99x forward multiple; and (3) the 42.48% gross margin failing to translate into operating leverage given $665 million of quarterly operating expenses ($387 million SG&A plus $170 million R&D). This Hold would upgrade to Buy on evidence of sequential revenue stabilization plus a signed divestiture at a credible valuation, or if the shares pull back toward the high-$70s where the risk/reward to the $98.24 target widens to roughly 25%+; it would downgrade to Sell if Q4 revenue declines again sequentially or if forward EPS estimates are cut below $4.50. On balance the stock is fairly valued to modestly undervalued relative to its own book-value history and in line with specialty-ingredient peers on forward earnings — not a bargain, but not a premium either.

Sign up to view all

IFF 12-Month Price Forecast

The forward view is genuinely two-sided: the sell-side consensus and the shallow $76 low target create a favorable asymmetry, but the 20.99x forward multiple requires a swing from trailing EPS of -$0.02 to $4.864 that the P&L has not begun to deliver. The 42.48% gross margin is the strongest evidence the mix shift toward Taste, Scent, and Health & Biosciences is working, yet the 7.73% operating margin shows that $665 million of quarterly operating expenses are absorbing nearly all of it. With the stock at 54.6% of its 52-week range, down 9.42% over the past month versus -2.26% for SPY, and having lost 15% in the eight sessions after the Q3 print, near-term momentum is clearly negative even as the one-year return remains +20.36%. I would upgrade to bullish on a signed divestiture at a credible valuation or on sequential revenue stabilization with operating margin above 10%, and downgrade to bearish if Q4 revenue declines again sequentially or forward EPS estimates fall below $4.50. Until one of those resolves, the appropriate stance is neutral with a bias toward accumulating on weakness toward the high-$70s.

Historical Price
Current Price $79.62
Average Target $90.00
High Target $110.00
Low Target $62.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on International Flavors & Fragrances's 12-month outlook, with a consensus price target around $98.24 and implied upside of +23.4% versus the current price.

Average Target

$98.24

20 analysts

Implied Upside

+23.4%

vs. current price

Analyst Count

20

covering this stock

Price Range

$76 - $110

Analyst target range

Buy
14 (70%)
Hold
5 (25%)
Sell
1 (5%)

Coverage is solid, with 17 analysts and a distribution of 14 Buy, 5 Hold, and 1 Sell, producing a consensus recommendation of "buy" and a recommendation mean of 1.9 (where 1.0 is a strong buy). The average target price of $98.24 implies roughly 21% upside from the current $81.16, a meaningful gap that suggests the sell-side is looking through the weak Q3 to the post-divestiture earnings power and the consensus forward EPS of $4.864. The consensus clearly leans bullish, and the recent institutional ratings flow supports that — Barclays reiterated Overweight on November 6, and Citigroup, JP Morgan, and UBS all reiterated constructive ratings on November 5, with no downgrades in the visible tape.

The target range of $76.00 to $110.00 is wide — a 45% spread between low and high — signaling genuine disagreement about the pace of the turnaround. The $110 high target likely assumes successful completion of the Food Ingredients divestiture, margin recovery toward the 42% gross margin level, debt paydown from proceeds, and a re-rating to a premium specialty-ingredients multiple; the $76 low target, which sits below the current price, likely prices in continued revenue erosion, failure to close the divestiture on favorable terms, and margin compression from cost inflation. Notably, the low target of $76 is only about 6% below the current price, meaning even the bear case does not envision a catastrophic outcome — a relatively reassuring signal. The pattern of reiterated (rather than upgraded) ratings suggests analysts are holding their positions pending divestiture clarity, and the wide spread means position sizing should account for the possibility that the stock trades toward the low end if Q4 results confirm the Q3 deterioration.

Drowning in data?

Find the real signal!

Bulls vs Bears: IFF Investment Factors

The bear case currently has stronger near-term evidence: a 27.9% revenue decline, a swing to a $55 million quarterly net loss, negative Q3 free cash flow, and a 15% post-earnings drawdown that erased market leadership. The bull case is forward-looking and rests on three verifiable pillars — gross margin already expanding to 42.48%, a 14-Buy/1-Sell analyst consensus with a $98.24 average target, and a $76 low target only 6.4% below spot that caps modeled downside. The single most important tension is whether the Food Ingredients divestiture closes on schedule in 2027 and at a valuation that funds debt paydown and buybacks; if it does, the post-divestiture earnings power justifies the 21x forward multiple, and if it slips or prices poorly, the current loss-making base has no valuation floor beyond book value at 1.22x. Until that catalyst resolves, the stock is a show-me story where the sell-side is paying for a future the P&L has not yet delivered.

Bullish

  • Analyst consensus firmly constructive: 14 of 17 analysts rate IFF a Buy against 5 Hold and 1 Sell, producing a recommendation mean of 1.9 and an average target of $98.24 — roughly 21% above the $81.16 price. The recent tape shows Barclays reiterating Overweight on November 6 and Citigroup, JP Morgan and UBS all reiterating constructive ratings on November 5, with no downgrades visible.
  • Even bear case is shallow: The lowest analyst target of $76.00 sits only about 6.4% below the current $81.16, meaning the sell-side's most pessimistic scenario does not envision a catastrophic outcome. That asymmetry — roughly 21% upside to consensus versus single-digit downside to the low target — frames a favorable risk/reward skew for patient holders.
  • Gross margin inflecting upward: Q3 2026 gross margin reached 42.48%, up sharply from 36.49% in Q3 2025 and above the 43.65% Q2 2026 level on a sequential basis when measured against the prior-year comparison. This margin expansion is the clearest evidence that mix shift toward Taste, Scent and Health & Biosciences is working even as headline revenue falls.
  • Divestiture refocuses portfolio on higher-growth core: The planned Food Ingredients divestiture, expected to close in 2027, would leave IFF concentrated in Taste (~25% of profits), Scent (~25%) and Health & Biosciences (~30%), the last being a global leader in probiotics and enzymes. Proceeds are earmarked for debt paydown and buybacks, which management is already executing at scale — $513 million of repurchases in Q3 alone.

Bearish

  • Revenue collapsing 27.9% year over year: Q3 2026 revenue of $1.942 billion fell 27.91% from $2.694 billion in Q3 2025, and the sequential path ($2.741B Q1, $1.954B Q2, $1.942B Q3) shows no stabilization. Consensus forward revenue of $8.52 billion implies only flat-to-modest recovery, so the top line is not yet a source of support.
  • Swing to net loss with negative trailing earnings: Q3 2026 produced a net loss of $55 million (EPS -$0.22) after $169 million of net income in Q1 and $50 million in Q2, a deteriorating intra-year trend. Trailing EPS of -$0.02 and trailing PE of -46.16x mean the entire 20.99x forward multiple rests on an earnings recovery that has not yet appeared.
  • Bloated cost structure versus gross margin: The gap between 42.5% gross margin and 7.7% operating margin is explained by $665 million of quarterly operating expenses, including $387 million of SG&A and $170 million of R&D. Q3 also absorbed $46 million of interest expense and $294 million of net other expenses, pushing pre-tax income to -$134 million.
  • Negative free cash flow while buying back stock: Q3 free cash flow was -$7 million despite $141 million of operating cash flow, as $148 million of capex and $102 million of dividends consumed the balance. Returning $513 million via buybacks in the same quarter is only sustainable if divestiture proceeds arrive as planned — a financing dependency, not a self-funded program.

IFF Technical Analysis

IFF is in a choppy but net-positive intermediate uptrend that has recently rolled over. The stock is up 20.36% over the trailing year and 19.30% year-to-date, but sits at $81.16, only about 54.6% of its 52-week range of $62.06 to $95.27 — meaning it has given back roughly half of its annual advance and is trading in the middle of the range rather than at highs. That positioning is neither momentum-chasing territory nor a falling-knife setup; it reflects a market that has rewarded the restructuring narrative but is unwilling to pay up ahead of divestiture clarity. Relative strength tells the same story: +8.09% versus SPY over one year, but -7.16% over the past month, a clear loss of leadership.

Short-term momentum has decelerated sharply and now diverges from the longer-term trend. The stock is down 9.42% over the past month and 3.59% over three months, versus a still-positive 11.03% six-month gain and +20.36% one-year gain — a classic late-cycle deceleration pattern where the trailing return is carried by earlier strength. The one-month decline of 9.42% compares with a -2.26% move in SPY, so IFF underperformed the market by roughly 7.16 percentage points in a month, and the selloff accelerated after the early-November Q3 report (the stock fell from $94.63 on November 2 to $80.38 by November 12, a roughly 15% drawdown in eight sessions). Volume data is reported as zero in the provided feed, so no accumulation/distribution read is possible, but the price action alone signals distribution into the print.

Key technical levels are well defined. Resistance sits at the 52-week high of $95.27, with the recent $94.63 November 2 close confirming a double-top-style rejection just below that level; a decisive breakout above $95 would signal the market is looking through the weak Q3 and pricing the post-divestiture earnings power. Support rests at the 52-week low of $62.06, with intermediate support likely in the high-$70s where the stock consolidated in July and August. Beta of 0.876 means the stock is roughly 12% less volatile than the market, which argues for larger position sizing on a risk-adjusted basis but also means the recent 15% drawdown was stock-specific rather than market-driven — a more concerning signal. Maximum drawdown of -19.73% over the period underscores that this is not a low-risk name despite the defensive end markets.

Beta

0.88

0.88x market volatility

Max Drawdown

-19.7%

Largest decline past year

52-Week Range

$62-$95

Price range past year

Annual Return

+23.3%

Cumulative gain past year

PeriodIFF ReturnS&P 500
1m-12.5%-9.7%
3m-5.5%-9.9%
6m+5.8%-7.5%
1y+23.3%+4.7%
ytd+17.0%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

IFF Fundamental Analysis

The revenue trajectory is the central problem: Q3 2026 revenue of $1.942 billion fell 27.91% year over year from $2.694 billion in Q3 2025, and the sequential trend is flat-to-down ($2.741 billion in Q1, $1.954 billion in Q2, $1.942 billion in Q3), implying the year-over-year collapse is partly portfolio/divestiture-related but also reflects genuine demand softness. Segment data for the quarter shows Scent at $689 million, Taste at $687 million, and Health & Biosciences at $566 million — a relatively balanced mix, but total segment revenue of $1.942 billion confirms no segment is offsetting the drag. The consensus revenue estimate of $8.52 billion for the forward period implies stabilization rather than recovery, and the investment case now hinges entirely on the Food Ingredients divestiture closing in 2027 and refocusing the portfolio on the higher-growth Taste, Scent, and H&B franchises.

Profitability is marginal and volatile. Q3 2026 produced a net loss of $55 million (EPS -$0.22) on gross margin of 42.48%, a notable improvement from the 36.49% gross margin in Q3 2025 but insufficient to cover $665 million of operating expenses, $46 million of interest expense, and $294 million of net other expenses. The quarterly net income path — $169 million in Q1, $50 million in Q2, -$55 million in Q3 — shows a deteriorating trend within the year, and trailing net margin is -3.31% with operating margin of 7.73%, both well below what a specialty ingredients franchise with this gross margin should earn. The gap between 42.5% gross margin and 7.7% operating margin points to a bloated cost structure (SG&A of $387 million plus R&D of $170 million in Q3) that management must address for the post-divestiture story to work.

Balance sheet and cash flow are adequate but not fortress-like. Debt-to-equity of 0.47 is moderate, current ratio of 1.42 provides reasonable liquidity, and trailing free cash flow of $499 million against a $17.25 billion market cap implies an FCF yield of roughly 2.9% — thin for a defensive compounder. ROE of -2.55% and ROA of 2.18% confirm the company is not currently earning its cost of capital, and Q3 free cash flow was actually -$7 million despite $141 million of operating cash flow, as $148 million of capex and $102 million of dividends consumed the balance. The company is returning capital aggressively ($513 million of buybacks in Q3 alone) while free cash flow is negative, which is only sustainable if divestiture proceeds arrive as planned.

Quarterly Revenue

$1.9B

2026-09

Revenue YoY Growth

-27.9%

YoY Comparison

Gross Margin

42.5%

Latest Quarter

Free Cash Flow

$499000000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Health & Biosciences
Scent
Taste

Open an Account, get $2 TSLA now!

Valuation Analysis: Is IFF Overvalued?

Because trailing net income is negative (EPS of -$0.02 and trailing PE of -46.16x), the PE ratio is not a usable primary metric; I therefore lead with the price-to-sales ratio of 1.58x and the forward PE of 20.99x. The forward PE is the more informative figure: it implies the market expects roughly $4.86 of forward EPS (consistent with the consensus estimate of $4.864), a dramatic swing from the current loss, and the gap between the meaningless trailing multiple and the 21x forward multiple tells you the entire valuation rests on earnings recovery that has not yet appeared. EV/EBITDA of 29.93x and EV/Sales of 2.48x both look rich relative to the 7.7% operating margin, reinforcing that the market is paying for the post-divestiture, higher-margin version of IFF rather than the current one.

Peer comparison is constrained because the provided valuation dataset does not include an explicit industry-average multiple, so a precise premium/discount spread cannot be quantified from the data. What can be said is that a 1.58x PS and 2.48x EV/Sales are modest in absolute terms for a specialty chemicals franchise with 42% gross margins, and the PEG ratio of 0.18 is extraordinarily low — though that figure is distorted by the negative trailing earnings base and should not be relied upon. The 20.99x forward PE sits in line with a market-multiple specialty ingredients peer group, suggesting the stock is neither conspicuously cheap nor expensive on normalized earnings; the discount implied by the 1.22x price-to-book is the more telling signal, reflecting that the market values IFF below the accounting value of its assets after years of impairment.

Historical context is the most useful lens here. The stock's own PS ratio has ranged from roughly 5.8x to 12.7x over the past several years on the historical ratios data, and the current 1.58x PS (per the valuation dataset) sits at the very bottom of that band — though the discrepancy between the 1.58x current figure and the 5.8x-10.9x historical quarterly PS readings reflects a change in share count or data methodology and should be treated cautiously. The price-to-book of 1.22x is near the low end of its multi-year range (which has run from roughly 1.02x to 1.82x), and the historical PE has swung wildly from -732x to +180x, making PE-based historical comparison meaningless. The takeaway is that IFF trades near the bottom of its own book-value band, which historically has marked value opportunities — but only when earnings are inflecting upward, which is not yet evidenced.

PE

-46.2x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 8x~181x

vs. Industry Avg

31.4x

Industry PE ~31.4x*

EV/EBITDA

29.9x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on a company that is currently not earning its cost of capital. Trailing ROE is -2.55% and ROA 2.18%, Q3 net income was -$55 million, and trailing net margin is -3.31% against a 7.73% operating margin — the spread between 42.48% gross margin and 7.73% operating margin quantifies a cost structure ($387 million SG&A plus $170 million R&D in Q3) that must be cut for the story to work. Free cash flow of $499 million TTM yields only about 2.9% on the $17.25 billion market cap, and Q3 FCF was actually -$7 million while the company repurchased $513 million of stock — a capital-return program funded by balance sheet and pending divestiture proceeds rather than organic cash generation. Debt-to-equity of 0.47 and a current ratio of 1.42 are adequate but leave limited cushion if the divestiture is delayed. Market and competitive risks are dominated by valuation compression and execution credibility. The 20.99x forward PE and 29.93x EV/EBITDA both price in a recovery that requires forward EPS of $4.864 versus trailing EPS of -$0.02 — a swing with no margin for error, and any Q4 confirmation of the Q3 deterioration would likely compress the multiple toward the $76 low target. Beta of 0.876 means only about 12% less volatility than the market, so the recent 15% drawdown was stock-specific rather than macro-driven, a more concerning signal; the stock has already underperformed SPY by 7.16 percentage points in a month and lost relative strength leadership. Competitive pressure in flavor and fragrance is real, and the Food Ingredients business being divested is the lower-margin, more commoditized piece — meaning the remaining core must sustain premium pricing against peers like Givaudan and Symrise. The worst-case scenario is a chain in which Q4 results confirm revenue erosion, the Food Ingredients divestiture slips past 2027 or prices below expectations, buybacks continue to consume cash the business is not generating, and analysts migrate toward the $76 low target. From $81.16, the 52-week low of $62.06 represents roughly -23.5% downside, and the stock's observed maximum drawdown of -19.73% over the period shows that a move of that magnitude is within its recent behavioral range. A realistic adverse outcome is a retest of the high-$70s consolidation zone (-5% to -10%) in the base bear case, with a full flight to the $62 area (-23.5%) if the divestiture thesis breaks.

FAQ

The most severe risk is execution on the Food Ingredients divestiture: if the deal slips past 2027 or prices below expectations, both the debt-paydown funding and the re-rating catalyst disappear, and the current loss-making base has no valuation floor beyond 1.22x book. Second is earnings risk — Q3 revenue fell 27.91% year over year to $1.942 billion and the company swung to a $55 million net loss, so a Q4 repeat would likely push analysts toward the $76 low target and compress the 20.99x forward multiple. Third is financial/cash-flow risk: trailing free cash flow of $499 million is only a ~2.9% yield, Q3 FCF was -$7 million, and the company repurchased $513 million of stock in the quarter — a capital-return program dependent on divestiture proceeds rather than organic cash generation. Fourth is competitive and margin risk: the 42.48% gross margin must be converted into operating leverage against $665 million of quarterly operating expenses, while the remaining core competes with Givaudan and Symrise on premium pricing. Ranked by severity: divestiture execution, earnings deterioration, cash-flow/financing dependency, then competitive margin pressure.

The 12-month outlook is split into three scenarios: a 50% base case of $82–$98 (divestiture grinds forward without a definitive announcement, revenue roughly flat sequentially, margins near 42%, average target near $98); a 30% bull case of $98–$110 (a signed divestiture at a credible multiple, sequential revenue stabilization, operating margin above 10%, and a re-rating toward the $98.24 average and $110 high target); and a 20% bear case of $62–$76 (Q4 confirms the Q3 deterioration, the divestiture slips, forward EPS is cut below $4.50, and the stock retests the high-$70s before sliding toward the $62.06 52-week low). The base case is most likely, and its key assumption is that forward EPS tracks near the $4.864 consensus, keeping the forward PE near 21x while the 14-Buy consensus holds the average target near $98. The distribution is deliberately skewed: the bear case is the smallest probability because even the lowest analyst target of $76 is only ~6.4% below spot, capping modeled downside.

The trailing PE of -46.16x is meaningless given negative trailing EPS, so the relevant metrics are the 20.99x forward PE, 1.58x price-to-sales, 2.48x EV/Sales, and 1.22x price-to-book. On forward earnings the stock is roughly in line with specialty-ingredient peers — the market is not paying a conspicuous premium, but it is also not demanding a discount. The more telling signal is the 1.22x price-to-book, which sits near the low end of its multi-year 1.02x–1.82x range, reflecting that the market values IFF below the accounting value of its assets after years of impairments. The 29.93x EV/EBITDA looks rich against a 7.73% operating margin, confirming that the multiple prices the post-divestiture, higher-margin version of IFF rather than the current one. Net, the stock is fairly valued to modestly undervalued relative to its own history, with the market implicitly expecting the divestiture to close and margins to expand — a discount would only emerge if shares retested the high-$70s.

From a pure risk/reward standpoint, IFF screens favorably: the $98.24 average analyst target implies roughly 21% upside from $81.16, while the $76 low target sits only about 6.4% below the current price, and 14 of 17 analysts rate it Buy. The catch is that the upside depends on an earnings recovery that has not yet appeared — trailing EPS is -$0.02, Q3 produced a $55 million net loss, and the 20.99x forward PE rests entirely on consensus EPS of $4.864. The biggest downside risk is a Q4 confirmation of the 27.91% revenue decline combined with a delayed Food Ingredients divestiture, which could pull shares toward the $62.06 52-week low (-23.5%). It is a reasonable buy for patient investors with a 12–24 month horizon who want exposure to a self-help restructuring at a 1.22x price-to-book near the bottom of its historical band, ideally accumulating on weakness toward the high-$70s. It is a poor fit for momentum traders or anyone who needs current profitability, given the negative free cash flow and the 15% post-earnings drawdown.

IFF is better suited to a medium-to-long-term holding period of at least 12–24 months than to short-term trading. The thesis is event-driven — the Food Ingredients divestiture is expected to close in 2027 — so the payoff depends on a catalyst that will not resolve within a quarter, and the stock's 20.36% one-year return alongside a -19.73% maximum drawdown shows it can swing widely in the interim. Beta of 0.876 means it is only about 12% less volatile than the market, and the recent 15% drawdown in eight sessions after the Q3 print was stock-specific rather than macro-driven, so short-term traders face meaningful gap risk around earnings. The 2.37% dividend yield provides a modest income cushion while waiting, though the payout ratio of -1.13 reflects that dividends are currently being funded despite negative earnings. A concrete minimum holding period of 18 months aligns with the expected 2027 divestiture close and gives the margin-recovery story time to show up in the P&L.